{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T05:15:50Z","timestamp":1793164550049,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T00:00:00Z","timestamp":1687737600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T00:00:00Z","timestamp":1687737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s00467-023-06025-6","type":"journal-article","created":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T06:02:21Z","timestamp":1687759341000},"page":"4001-4011","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Long-term outcomes with rituximab as add-on therapy in severe childhood-onset lupus nephritis"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1463-6005","authenticated-orcid":false,"given":"Eugene Yu-hin","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sze-wa","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona Fung-yee","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsz-wai","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pak-chiu","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wai-ming","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison Lap-tak","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desmond Yat-hin","family":"Yap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,26]]},"reference":[{"key":"6025_CR1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/art.24091","volume":"61","author":"AO Hersh","year":"2009","unstructured":"Hersh AO, von Scheven E, Yazdany J, Panopalis P, Trupin L, Julian L, Katz P, Criswell LA, Yelin E (2009) Differences in long-term disease activity and treatment of adult patients with childhood-and adult-onset systemic lupus erythematosus. Arthritis Rheum 61:13\u201320","journal-title":"Arthritis Rheum"},{"key":"6025_CR2","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2215\/CJN.07810621","volume":"17","author":"SE Wenderfer","year":"2022","unstructured":"Wenderfer SE, Chang JC, Davies AG, Luna IY, Scobell R, Sears C, Magella B, Mitsnefes M, Stotter BR, Dharnidharka VR (2022) Using a multi-institutional pediatric learning health system to identify systemic lupus erythematosus and lupus nephritis: development and validation of computable phenotypes. Clin J Am Soc Nephrol 17:65\u201374","journal-title":"Clin J Am Soc Nephrol"},{"key":"6025_CR3","doi-asserted-by":"publisher","unstructured":"De Mutiis C, Wenderfer SE, Orjuela A, Bagga A, Basu B, Sar T, Aggarwal A, Jain A, Yap HK, Ito S, Ohnishi A, Iwata N, Kasapcopur O, Laurent A, Mastrangelo A, Ogura M, Shima Y, Rianthavorn P, Silva CA, Trindade V, Dormi A, Tullus K\u00a0(2022)\u00a0Defining renal remission in an international cohort of 248 children and adolescents with lupus nephritis. Rheumatology (Oxford) 61(6):2563\u20132571. https:\/\/doi.org\/10.1093\/rheumatology\/keab746","DOI":"10.1093\/rheumatology\/keab746"},{"key":"6025_CR4","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.ekir.2022.10.014","volume":"8","author":"EY Chan","year":"2023","unstructured":"Chan EY, Yap DY, Wong WT, Wong WH, Wong SW, Lin KY, Hui FY, Yee-Ming J, Lam SS, Wong JK, Lai FF, Ho TW, Tong PC, Lai WM, Chan TM, Ma AL (2023) Long-term outcomes of children and adolescents with biopsy-proven childhood-onset lupus nephritis. Kidney Int Rep 8:141\u2013150. https:\/\/doi.org\/10.1016\/j.ekir.2022.10.014","journal-title":"Kidney Int Rep"},{"key":"6025_CR5","doi-asserted-by":"publisher","first-page":"3248","DOI":"10.1093\/ndt\/gfs073","volume":"27","author":"DY Yap","year":"2012","unstructured":"Yap DY, Tang CS, Ma MK, Lam MF, Chan TM (2012) Survival analysis and causes of mortality in patients with lupus nephritis. Nephrol Dial Transplant 27:3248\u20133254","journal-title":"Nephrol Dial Transplant"},{"key":"6025_CR6","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/nep.14007","volume":"27","author":"EYH Chan","year":"2022","unstructured":"Chan EYH, Yap DYH, Wong WHS, Ho TW, Tong PC, Lai WM, Chan TM, Ma ALT (2022) Demographics and long-term outcomes of children with end-stage kidney disease: a 20-year territory-wide study. Nephrology (Carlton) 27:171\u2013180. https:\/\/doi.org\/10.1111\/nep.14007","journal-title":"Nephrology (Carlton)"},{"key":"6025_CR7","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1007\/s00467-020-04686-1","volume":"36","author":"L Oni","year":"2021","unstructured":"Oni L, Wright RD, Marks S, Beresford MW, Tullus K (2021) Kidney outcomes for children with lupus nephritis. Pediatr Nephrol 36:1377\u20131385","journal-title":"Pediatr Nephrol"},{"key":"6025_CR8","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","volume":"100","author":"BH Rovin","year":"2021","unstructured":"Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM, Cook HT, Fervenza FC, Gibson KL, Glassock RJ (2021) KDIGO 2021 Clinical Practice Guideline for the management of glomerular diseases. Kidney Int Suppl 100:S1\u2013S276","journal-title":"Kidney Int Suppl"},{"key":"6025_CR9","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1007\/s00467-020-04788-w","volume":"36","author":"EYH Chan","year":"2021","unstructured":"Chan EYH, Ma ALT, Tullus K (2021) When should we start and stop ACEi\/ARB in paediatric chronic kidney disease? Pediatr Nephrol 36:1751\u20131764. https:\/\/doi.org\/10.1007\/s00467-020-04788-w","journal-title":"Pediatr Nephrol"},{"key":"6025_CR10","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1007\/s00467-020-04609-0","volume":"36","author":"EY-h Chan","year":"2021","unstructured":"Chan EY-h, Tullus K (2021) Rituximab in children with steroid sensitive nephrotic syndrome: in quest of the optimal regimen. Pediatr Nephrol 36:1397\u20131405. https:\/\/doi.org\/10.1007\/s00467-020-04609-0","journal-title":"Pediatr Nephrol"},{"key":"6025_CR11","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1053\/j.ajkd.2022.05.013","volume":"81","author":"M Marlais","year":"2022","unstructured":"Marlais M, Wlodkowski T, Printza N, Kronsteiner D, Krisam R, Sauer L, Aksenova M, Ashoor I, Awan A, Bacchetta J (2022) Clinical factors and adverse kidney outcomes in children with ANCA-associated glomerulonephritis. Am J Kidney Dis 81:119\u2013122. https:\/\/doi.org\/10.1053\/j.ajkd.2022.05.013","journal-title":"Am J Kidney Dis"},{"key":"6025_CR12","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.kint.2019.09.033","volume":"97","author":"EY-h Chan","year":"2020","unstructured":"Chan EY-h, Webb H, Yu E, Ghiggeri GM, Kemper MJ, Ma AL-t, Yamamura T, Sinha A, Bagga A, Hogan J (2020) Both the rituximab dose and maintenance immunosuppression in steroid-dependent\/frequently-relapsing nephrotic syndrome have important effects on outcomes. Kidney Int. 97:393\u2013401. https:\/\/doi.org\/10.1016\/j.kint.2019.09.033","journal-title":"Kidney Int."},{"key":"6025_CR13","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2215\/CJN.08570722","volume":"18","author":"EY Chan","year":"2022","unstructured":"Chan EY, Yap DY, Colucci M, Ma AL, Parekh RS, Tullus K (2022) Use of rituximab in childhood idiopathic nephrotic syndrome. Clin J Am Soc Nephrol 18:533\u2013548. https:\/\/doi.org\/10.2215\/CJN.08570722","journal-title":"Clin J Am Soc Nephrol"},{"key":"6025_CR14","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1681\/ASN.2021111472","volume":"33","author":"EY Chan","year":"2022","unstructured":"Chan EY, Ellen L, Angeletti A, Arslan Z, Basu B, Boyer O, Chan C-Y, Colucci M, Dorval G, Dossier C (2022) Long-term efficacy and safety of repeated rituximab to maintain remission in idiopathic childhood nephrotic syndrome: an international study. J Am Soc Nephrol 33:1193\u20131207. https:\/\/doi.org\/10.1681\/ASN.2021111472","journal-title":"J Am Soc Nephrol"},{"key":"6025_CR15","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1007\/s00467-021-05345-9","volume":"37","author":"EY Chan","year":"2022","unstructured":"Chan EY, Ma AL, Tullus K (2022) Hypogammaglobulinaemia following rituximab therapy in childhood nephrotic syndrome. Pediatr Nephrol 37:927\u2013931. https:\/\/doi.org\/10.1007\/s00467-021-05345-9","journal-title":"Pediatr Nephrol"},{"key":"6025_CR16","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s12969-021-00627-w","volume":"19","author":"M Gilbert","year":"2021","unstructured":"Gilbert M, Goilav B, Hsu JJ, Nietert PJ, Meidan E, Chua A, Ardoin SP, Wenderfer SE, von Scheven E, Ruth NM, Pediatric Nephrology and Rheumatology Collaborative Group, the Childhood Arthritis and Rheumatology Research Alliance, and the American Society for Pediatric Nephrology (2021) Differences in rituximab use between pediatric rheumatologists and nephrologists for the treatment of refractory lupus nephritis and renal flare in childhood-onset SLE. Pediatr Rheumatol Online 19:137","journal-title":"Pediatr Rheumatol Online"},{"key":"6025_CR17","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1136\/adc.2007.126276","volume":"93","author":"A Podolskaya","year":"2008","unstructured":"Podolskaya A, Stadermann M, Pilkington C, Marks SD, Tullus K (2008) B cell depletion therapy for 19 patients with refractory systemic lupus erythematosus. Arch Dis Child 93:401\u2013406","journal-title":"Arch Dis Child"},{"key":"6025_CR18","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s00467-007-0694-9","volume":"23","author":"O Nwobi","year":"2008","unstructured":"Nwobi O, Abitbol CL, Chandar J, Seeherunvong W, Zilleruelo G (2008) Rituximab therapy for juvenile-onset systemic lupus erythematosus. Pediatr Nephrol 23:413\u2013419","journal-title":"Pediatr Nephrol"},{"key":"6025_CR19","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s00467-017-3767-4","volume":"33","author":"J Hogan","year":"2018","unstructured":"Hogan J, Godron A, Baudouin V, Kwon T, Harambat J, Desch\u00eanes G, Niel O (2018) Combination therapy of rituximab and mycophenolate mofetil in childhood lupus nephritis. Pediatr Nephrol 33:111\u2013116","journal-title":"Pediatr Nephrol"},{"key":"6025_CR20","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1007\/s00467-017-3583-x","volume":"32","author":"B Basu","year":"2017","unstructured":"Basu B, Roy B, Babu BG (2017) Efficacy and safety of rituximab in comparison with common induction therapies in pediatric active lupus nephritis. Pediatr Nephrol 32:1013\u20131021","journal-title":"Pediatr Nephrol"},{"key":"6025_CR21","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1177\/0961203314547793","volume":"24","author":"L Watson","year":"2015","unstructured":"Watson L, Beresford M, Maynes C, Pilkington C, Marks S, Glackin Y, Tullus K (2015) The indications, efficacy and adverse events of rituximab in a large cohort of patients with juvenile-onset SLE. Lupus 24:10\u201317","journal-title":"Lupus"},{"key":"6025_CR22","doi-asserted-by":"publisher","first-page":"3168","DOI":"10.1002\/art.21351","volume":"52","author":"SD Marks","year":"2005","unstructured":"Marks SD, Patey S, Brogan PA, Hasson N, Pilkington C, Woo P, Tullus K (2005) B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum 52:3168\u20133174","journal-title":"Arthritis Rheum"},{"key":"6025_CR23","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.ekir.2021.12.005","volume":"7","author":"DY Yap","year":"2022","unstructured":"Yap DY, Li PH, Tang C, So BY, Kwan LP, Chan GC, Lau CS, Chan TM (2022) Long-term results of triple immunosuppression with tacrolimus added to mycophenolate and corticosteroids in the treatment of lupus nephritis. Kidney Int Rep 7:516\u2013525","journal-title":"Kidney Int Rep"},{"key":"6025_CR24","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.3899\/jrheum.170226","volume":"44","author":"DY Yap","year":"2017","unstructured":"Yap DY, Tang C, Ma MK, Mok MM, Chan GC, Kwan LP, Chan TM (2017) Longterm data on disease flares in patients with proliferative lupus nephritis in recent years. J Rheumatol 44:1375\u20131383","journal-title":"J Rheumatol"},{"key":"6025_CR25","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1002\/art.1780251101","volume":"25","author":"EM Tan","year":"1982","unstructured":"Tan EM, Cohen AS, Fries JF, Masi AT, Mcshane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271\u20131277","journal-title":"Arthritis Rheum"},{"key":"6025_CR26","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/sj.ki.5002118","volume":"71","author":"G Markowitz","year":"2007","unstructured":"Markowitz G, D\u2019Agati V (2007) The ISN\/RPS 2003 classification of lupus nephritis: an assessment at 3 years. Kidney Int 71:491\u2013495","journal-title":"Kidney Int"},{"key":"6025_CR27","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1681\/ASN.2008030287","volume":"20","author":"GJ Schwartz","year":"2009","unstructured":"Schwartz GJ, Munoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, Furth SL (2009) New equations to estimate GFR in children with CKD. J Am Soc Nephrol 20:629\u2013637","journal-title":"J Am Soc Nephrol"},{"key":"6025_CR28","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1093\/clinchem\/hvab278","volume":"68","author":"WG Miller","year":"2021","unstructured":"Miller WG, Kaufman HW, Levey AS, Straseski JA, Wilhelms KW, Yu H-YE, Klutts JS, Hilborne LH, Horowitz GL, Lieske J (2021) National Kidney Foundation Laboratory Engagement Working Group recommendations for implementing the CKD-EPI 2021 race-free equations for estimated glomerular filtration rate: practical guidance for clinical laboratories. Clin Chem 68:511\u2013520. https:\/\/doi.org\/10.1093\/clinchem\/hvab278","journal-title":"Clin Chem"},{"key":"6025_CR29","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1177\/0961203315615220","volume":"25","author":"E Aragon","year":"2016","unstructured":"Aragon E, Resontoc L, Chan Y, Lau Y, Tan P, Loh H, Ng K, Yap H (2016) Long-term outcomes with multi-targeted immunosuppressive protocol in children with severe proliferative lupus nephritis. Lupus 25:399\u2013406","journal-title":"Lupus"},{"key":"6025_CR30","doi-asserted-by":"publisher","first-page":"7917","DOI":"10.3390\/ijms16047917","volume":"16","author":"DY Yap","year":"2015","unstructured":"Yap DY, Lai KN (2015) Pathogenesis of renal disease in systemic lupus erythematosus\u2013the role of autoantibodies and lymphocytes subset abnormalities. Int J Mol Sci 16:7917\u20137931","journal-title":"Int J Mol Sci"},{"key":"6025_CR31","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1002\/art.34359","volume":"64","author":"BH Rovin","year":"2012","unstructured":"Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, Maciuca R, Zhang D, Garg JP, Brunetta P (2012) Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study. Arthritis Rheum 64:1215\u20131226","journal-title":"Arthritis Rheum"},{"key":"6025_CR32","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1093\/ndt\/gfab152","volume":"37","author":"S Demir","year":"2021","unstructured":"Demir S, G\u00fclhan B, \u00d6zen S, \u00c7ele\u011fen K, Batu ED, Ta\u015f N, Orhan D, Bilginer Y, D\u00fczova A, Ozaltin F (2021) Long-term renal survival of paediatric patients with lupus nephritis. Nephrol Dial Transplant 37:1069\u20131077. https:\/\/doi.org\/10.1093\/ndt\/gfab152","journal-title":"Nephrol Dial Transplant"},{"key":"6025_CR33","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s00467-021-05164-y","volume":"37","author":"S Qiu","year":"2021","unstructured":"Qiu S, Zhang H, Yu S, Yang Q, Zhang G, Yang H, Li Q, Wang M (2021) Clinical manifestations, prognosis, and treat-to-target assessment of pediatric lupus nephritis. Pediatr Nephrol 37:367\u2013376. https:\/\/doi.org\/10.1007\/s00467-021-05164-y","journal-title":"Pediatr Nephrol"},{"key":"6025_CR34","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1191\/0961203305lu2081oa","volume":"14","author":"T Chan","year":"2005","unstructured":"Chan T, Tse K, Tang CS, Lai K, Li F (2005) Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine. Lupus 14:265\u2013272","journal-title":"Lupus"},{"key":"6025_CR35","doi-asserted-by":"publisher","unstructured":"Chan EY, Liu MS, Or PC, Ma AL (2022) Outcomes and perception of cloud-based remote patient monitoring in children receiving automated peritoneal dialysis: a prospective study. Pediatr Nephrol 38:2171\u20132178. https:\/\/doi.org\/10.1007\/s00467-022-05828-3","DOI":"10.1007\/s00467-022-05828-3"},{"key":"6025_CR36","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1177\/0961203308097570","volume":"18","author":"P Hari","year":"2009","unstructured":"Hari P, Bagga A, Mahajan P, Dinda A (2009) Outcome of lupus nephritis in Indian children. Lupus 18:348\u2013354","journal-title":"Lupus"},{"key":"6025_CR37","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1007\/s00467-006-0052-3","volume":"21","author":"S-N Wong","year":"2006","unstructured":"Wong S-N, Tse K-C, Lee T-L, Lee K-W, Chim S, Lee K-P, Wai-Po Chu R, Chan W, Fong K-W, Hui J (2006) Lupus nephritis in Chinese children\u2013a territory-wide cohort study in Hong Kong. Pediatr Nephrol 21:1104\u20131112","journal-title":"Pediatr Nephrol"},{"key":"6025_CR38","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1093\/ndt\/gfp173","volume":"24","author":"P Vachvanichsanong","year":"2009","unstructured":"Vachvanichsanong P, Dissaneewate P, McNeil E (2009) Diffuse proliferative glomerulonephritis does not determine the worst outcome in childhood-onset lupus nephritis: a 23-year experience in a single centre. Nephrol Dial Transplant 24:2729\u20132734","journal-title":"Nephrol Dial Transplant"},{"key":"6025_CR39","doi-asserted-by":"publisher","first-page":"220","DOI":"10.3390\/pediatric14020030","volume":"14","author":"SE Wenderfer","year":"2022","unstructured":"Wenderfer SE, Orjuela A, Bekheirnia MR, Pereira M, Muscal E, Braun MC, De Guzman M (2022) Lupus nephritis, autoantibody production and kidney outcomes in males with childhood-onset systemic lupus erythematosus. Pediatr Rep 14:220\u2013232","journal-title":"Pediatr Rep"},{"key":"6025_CR40","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1080\/1744666X.2022.2056020","volume":"18","author":"DYH Yap","year":"2022","unstructured":"Yap DYH, Chan TM (2022) What is the ideal duration of maintenance therapy for lupus nephritis? Expert Rev Clin Immunol 18:425\u2013427","journal-title":"Expert Rev Clin Immunol"},{"key":"6025_CR41","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jaut.2018.03.003","volume":"91","author":"T Kraaij","year":"2018","unstructured":"Kraaij T, Kamerling SWA, de Rooij ENM, van Daele PLA, Bredewold OW, Bakker JA, Bajema IM, Scherer HU, Toes REM, Huizinga TJW, Rabelink TJ, van Kooten C, Teng YKO (2018) The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus. J Autoimmun 91:45\u201354","journal-title":"J Autoimmun"},{"key":"6025_CR42","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-025687","volume":"9","author":"YKO Teng","year":"2019","unstructured":"Teng YKO, Bruce IN, Diamond B, Furie RA, van Vollenhoven RF, Gordon D, Groark J, Henderson RB, Oldham M, Tak PP (2019) Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol. BMJ Open 9:e025687","journal-title":"BMJ Open"},{"key":"6025_CR43","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","volume":"81","author":"RA Furie","year":"2022","unstructured":"Furie RA, Aroca G, Cascino MD, Garg JP, Rovin BH, Alvarez A, Fragoso-Loyo H, Zuta-Santillan E, Schindler T, Brunetta P, Looney CM, Hassan I, Malvar A (2022) B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 81:100\u2013107","journal-title":"Ann Rheum Dis"},{"key":"6025_CR44","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","volume":"397","author":"BH Rovin","year":"2021","unstructured":"Rovin BH, Teng YKO, Ginzler EM, Arriens C, Caster DJ, Romero-Diaz J, Gibson K, Kaplan J, Lisk L, Navarra S, Parikh SV, Randhawa S, Solomons N, Huizinga RB (2021) Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 397:2070\u20132080. https:\/\/doi.org\/10.1016\/S0140-6736(21)00578-X","journal-title":"Lancet"},{"key":"6025_CR45","doi-asserted-by":"publisher","first-page":"R33","DOI":"10.1186\/ar3738","volume":"14","author":"EM Ginzler","year":"2012","unstructured":"Ginzler EM, Wax S, Rajeswaran A, Copt S, Hillson J, Ramos E, Singer NG (2012) Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis Res Ther 14:R33","journal-title":"Arthritis Res Ther"},{"key":"6025_CR46","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.3389\/fimmu.2019.01653","volume":"10","author":"M Colucci","year":"2019","unstructured":"Colucci M, Carsetti R, Serafinelli J, Rocca S, Massella L, Gargiulo A, Lo Russo A, Capponi C, Cotugno N, Porzio O (2019) Prolonged impairment of immunological memory after anti-CD20 treatment in pediatric idiopathic nephrotic syndrome. Front Immunol 10:1653","journal-title":"Front Immunol"},{"key":"6025_CR47","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1177\/0961203314525248","volume":"23","author":"D Yap","year":"2014","unstructured":"Yap D, Yung S, Ma M, Mok M, Kwan L, Chan G, Chan T (2014) Serum immunoglobulin G level in patients with lupus nephritis and the effect of treatment with corticosteroids and mycophenolate mofetil. Lupus 23:678\u2013683. https:\/\/doi.org\/10.1177\/0961203314525248","journal-title":"Lupus"},{"key":"6025_CR48","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1093\/rheumatology\/key394","volume":"58","author":"S Wijetilleka","year":"2019","unstructured":"Wijetilleka S, Jayne DR, Mukhtyar C, Ala A, Bright PD, Chinoy H, Harper L, Kazmi MA, Kiani-Alikhan S, Li CK (2019) Recommendations for the management of secondary hypogammaglobulinaemia due to B cell targeted therapies in autoimmune rheumatic diseases. Rheumatology (Oxford) 58:889\u2013896","journal-title":"Rheumatology (Oxford)"},{"key":"6025_CR49","doi-asserted-by":"publisher","unstructured":"Ma AL, Leung D, Chan EY, Chim S, Cheng S, Ho FT, Lai WM, Tong PC, Lee MH, Wong WH, Chan SM, Rosa Duque J, Peiris JSM, Lau YL (2022) Antibody responses to 2 doses of mRNA COVID-19 vaccine in pediatric patients with\u00a0kidney diseases. Kidney Int 101(5):1069\u20131072. https:\/\/doi.org\/10.1016\/j.kint.2022.01.035","DOI":"10.1016\/j.kint.2022.01.035"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-023-06025-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-023-06025-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-023-06025-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T12:04:58Z","timestamp":1697630698000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-023-06025-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,26]]},"references-count":49,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["6025"],"URL":"https:\/\/doi.org\/10.1007\/s00467-023-06025-6","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,26]]},"assertion":[{"value":"22 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}